No knife needed? new trial tests if chemo and radiation alone can cure breast cancer

NCT ID NCT06498154

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether women with certain aggressive breast cancers (triple negative or HER2-positive) can safely avoid breast surgery if their tumors disappear completely after a combination of chemotherapy and radiation. The study will enroll 200 women and follow them for 5 years to see if the cancer stays away. If it works, it could spare many patients from surgery and its recovery time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

chemotherapy (TCb regimen with or without immunotherapy for triple negative; TCb plus trastuzumab and pertuzumab for HER2+) and radiotherapy (whole-breast irradiation plus boost)

What this could lead to

If successful, this could show that some breast cancer patients can avoid surgery entirely after strong chemo and radiation, reducing treatment burden.

What could go wrong

This is a phase 2 trial with only 200 people, so results are preliminary. There is a risk that cancer may return without surgery, and the combination of chemo and radiation may cause more side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin medical university cancer institute and hospital

    RECRUITING

    Tianjin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••